print PRINT

SCIENCE > Health

Avigan approval delayed due to lack of subjects for clinical tests  

  • June 10, 2020
  • , Yomiuri
  • JMH Summary

Yomiuri wrote that the GOJ’s plan to swiftly approve the anti-flu drug Avigan for treatment of the new coronavirus has hit a snag because clinical trials have been delayed due to a lack of COVID-19 patients for the trials. The paper wrote that although Fujifilm Holdings Corp., the developer of Avigan, is planning to enroll 96 COVID-19 patients in the testing, it is having difficulty finding patients who are showing relatively minor pneumonia symptoms because the number of new patients has been declining since mid-April. The paper wrote that the approval could be delayed further because the trials may not be finished until July. 

  • Ambassador
  • Ukraine
  • COVID-19
  • Trending Japan